Lensar (LNSR) Cash from Financing Activities (2019 - 2026)
Lensar (LNSR) posted quarterly Cash from Financing Activities of -$209000.0 for Q1 2026, down 102.16% year-over-year from $9.7 million in Q1 2025, and down 144.09% quarter-over-quarter from $474000.0 in Q4 2025.
Lensar (LNSR) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Lensar (LNSR) has reported Cash from Financing Activities for 8 consecutive years, with -$209000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 102.16% year-over-year to -$209000.0; the TTM figure through Mar 2026 stood at $358000.0 (down 96.38% YoY), while the FY2025 annual figure was $10.3 million, up 13051.28% from the prior year.
- Cash from Financing Activities eased to -$209000.0 in Q1 2026 per LNSR's latest filing, from $474000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $9.7 million in Q1 2025 and bottomed at -$1.2 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $755333.3 across 5 years, with a median of $111000.0 in 2024.
- Annual changes were most pronounced in 2025 — Cash from Financing Activities surged 7554.62% — and 2026, when it tumbled 102.16%.
- Lensar's Cash from Financing Activities stood at $196000.0 in 2022, then dropped by 25.51% to $146000.0 in 2023, then grew by 17.81% to $172000.0 in 2024, then soared by 175.58% to $474000.0 in 2025, then tumbled by 144.09% to -$209000.0 in 2026.
- Business Quant data shows LNSR's Cash from Financing Activities at -$209000.0 in Q1 2026, $474000.0 in Q4 2025, and $93000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Lensar | 103.79 Mn | 90.22 Mn | 9.78 Mn | 233,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 233,000.00 |
| Jun 30, 2026 | 233,000.00 |
| Mar 31, 2026 | -209,000.00 |
| Mar 31, 2026 | -209,000.00 |
| Dec 31, 2025 | 474,000.00 |
| Dec 31, 2025 | 474,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Mar 31, 2025 | 9.69 Mn |
| Mar 31, 2025 | 9.69 Mn |
| Dec 31, 2024 | 172,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Sep 30, 2024 | -93,000.00 |
| Sep 30, 2024 | -93,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Mar 31, 2024 | -130,000.00 |
| Mar 31, 2024 | -130,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Dec 31, 2023 | 146,000.00 |